Document is current
Any future updates will be listed below
-
Authors
Akagbosu, Blossom
Tayyebi, Zakieh https://orcid.org/0000-0002-7821-9905
Shibu, Gayathri
Paucar Iza, Yoselin A.
Deep, Deeksha
Parisotto, Yollanda Franco
Fisher, Logan https://orcid.org/0000-0003-4680-1527
Pasolli, H. Amalia
Thevin, Valentin https://orcid.org/0000-0002-0548-1160
Elmentaite, Rasa https://orcid.org/0000-0001-7366-5466
Knott, Maximilian https://orcid.org/0000-0002-6995-3702
Hemmers, Saskia https://orcid.org/0000-0002-5575-0509
Jahn, Lorenz https://orcid.org/0000-0002-9880-7026
Friedrich, Christin
Verter, Jacob https://orcid.org/0000-0003-3710-6549
Wang, Zhong-Min https://orcid.org/0000-0002-5538-1969
van den Brink, Marcel https://orcid.org/0000-0003-0696-4401
Gasteiger, Georg https://orcid.org/0000-0001-6986-127X
Grünewald, Thomas G. P. https://orcid.org/0000-0003-0920-7377
Marie, Julien C. https://orcid.org/0000-0001-6713-7923
Leslie, Christina https://orcid.org/0000-0002-4571-5910
Rudensky, Alexander Y. https://orcid.org/0000-0003-1280-2898
Brown, Chrysothemis C. https://orcid.org/0000-0002-5834-926X
- License Information
-
More Information
Article History
Received: 9 May 2021
Accepted: 1 September 2022
First Online: 7 September 2022
Competing interests
: M.v.d.B. has received research support and stock options from Seres Therapeutics and stock options from Notch Therapeutics and Pluto Therapeutics; he has received royalties from Wolters Kluwer; has consulted, received honorarium from or participated in advisory boards for Seres Therapeutics, WindMIL Therapeutics, Rheos Medicines, Merck & Co., Magenta Therapeutics, Frazier Healthcare Partners, Nektar Therapeutics, Notch Therapeutics, Forty Seven, Priothera, Ceramedix, Lygenesis, Pluto Therapeutics, GlaskoSmithKline, Da Volterra, Vor BioPharma, Novartis (spouse), Synthekine (spouse) and Beigene (spouse); he has intellectual property licensed to Seres Therapeutics and Juno Therapeutics; and holds a fiduciary role on the Foundation Board of DKMS (a nonprofit organization). A.Y.R. is a member of the scientific advisory board and has equity in Surface Oncology and RAPT Therapeutics, and holds intellectual property licensed to Takeda, which is not related to the content of this study.
